Pulmonx Corporation (LUNG) Reports In-Line Q1 EPS; Offers FY23 Revenue Guidance

Pulmonx Corporation (NASDAQ: LUNG) reported Q1 EPS of ($0.42), in-line with the analyst estimate of ($0.42). Revenue for the quarter came in at $14.5 million versus the consensus estimate of $13.58 million.

GUIDANCE:

Pulmonx Corporation sees FY2023 revenue of $63-65 million, versus the consensus of $64.4 million.

For earnings history and earnings-related data on Pulmonx Corporation (LUNG) click here.

You May Also Be Interested In

• MillerKnoll, Inc. (MLKN) Tops Q4 EPS by 4c
• KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook
• Morgan Stanley raises dividend 15% and approves $20B buyback program